Introduction {#s0001}
============

Transforming Growth Factor β (TGF-β) and Bone Morphogenetic Protein (BMP) signal transduction routes in the cell are implicated in various cellular processes. Both signaling pathways start with the activation of a transmembrane receptor pair located at the plasma membrane. Receptor activation causes phosphorylation of downstream receptor-activated proteins called Sma and Mad (SMADs).[@cit0001] These receptor-activated SMADs (R-SMADs) in turn bind to SMAD4 as a heterotrimeric protein complex to regulate gene transcription. Depending on the activating signaling ligand, different R-SMAD proteins become activated. BMP causes phosphorylation of SMAD1/5/9, while TGF-β causes phosphorylation of SMAD2/3. The SMAD-mediated signaling routes are regulated by the SMAD6 and SMAD7 as negative regulators.

Activated SMAD complexes are able to interact with transcription factors and co-localize to specific genomic locations[@cit0004] Furthermore, SMAD complexes bind to the coactivator complex p300 and the PCAF histone acetyltransferases.[@cit0006] Recruitment of p300 or the PCAF subunit of SAGA and ATAC complexes[@cit0009] stimulates gene transcription via the acetylation of histone tails in proximity of the complex. In addition, proteins containing double bromodomains or certain plant homeodomain (PHD) fingers recognize and bind acetylated histones.[@cit0010]

Other histone modifications that are associated with active gene transcription are H3K4 mono- and trimethylation. H3K4 trimethylation (H3K4me3) is present on the promoters of active genes and is a binding site for the TFIID subunit TAF3.[@cit0014] H3K4 monomethylation (H3K4me1) is found at active enhancer sites. H3K4 methylation is carried out by the six SET1/MLL methyltransferase complex types present in human cells. SET domain-containing protein 1A (SET1A) and SET1B complexes are responsible for the bulk of H3K4 trimethylation[@cit0015] while Mixed Lineage Leukemia 3 (MLL3, also named lysine methyl transferase 2C (KMT2C)) and MLL4 (KMT2D) complexes are maintaining H3K4 mono-methylation at enhancer sites.[@cit0016]

The SET1/MLL complexes all contain the WDR5, RBBP5, ASH2L and DPY30 proteins that make up the common WRAD core.[@cit0018] In addition to the WRAD core, the MLL3 and MLL4 complexes are composed of Pax Transactivation domain-Interacting Protein (PTIP) and PTIP Interacting protein 1 (PA1).[@cit0018] Apart from interacting in the MLL3 and MLL4 methyltransferases, PTIP and PA1 also form a distinct protein complex that can exist and act independently during DNA damage and IgH class switching.[@cit0018] SMAD2 was previously identified as an interaction partner of PTIP.[@cit0018] However, the link to the MLL3 and MLL4 methyltransferases has not been clarified yet.

Here, we report the relationship between SMAD-mediated signaling and the gene regulatory function of PTIP. In a comprehensive approach, we determined the interaction of PTIP and PA1 proteins with all SMADs to identify a link between the TGF-β SMADs and PTIP and PA1. Gene expression analysis following PTIP and PA1 knockdown confirms PTIP and PA1 to be involved in TGF-β gene activation. Expression analysis after MLL3 and MLL4 knockdown shows this activation to be MLL4 but not MLL3 dependent. This links SMAD signaling to the MLL4 methyltransferase complex.

Results {#s0002}
=======

*PTIP and PA1 bind to TGF-β activated SMADs* -- The interaction of PTIP and SMAD2 has been identified and studied before[@cit0023] and was confirmed previously by us using an unbiased proteomics approach.[@cit0018] We hypothesized that other SMAD family members could interact with PTIP. To systematically identify the SMAD proteins binding to PTIP, HEK 293T cells were co-transfected with HA-tagged SMAD and GFP-PTIP expression plasmids and affinity purification was performed via the GFP-tag of GFP-PTIP. Immunoblotting with the HA-antibody revealed the presence of TGF-β activated SMAD2, 3 and 4 in the GFP purifications, while BMP stimulated SMAD1 and 5 were absent ([Fig. 1A](#f0001){ref-type="fig"}). We have previously demonstrated that these SMAD1 and 5 expression constructs result in functional SMAD proteins.[@cit0024] Interestingly, SMAD9 was also present at low levels. PTIP and PA1 are subunits of the MLL3 and MLL4 methyltransferase complexes. Additionally, PTIP and PA1 can form independent heterodimer complexes. To examine the interaction of SMADs with PA1, HEK 293T cells were similarly co-transfected with HA-SMADs and GFP-PA1. GFP-affinity purification on the transfected cell lysates also showed interaction with the TGF-β SMADs ([Fig. 1B](#f0001){ref-type="fig"}). Interestingly, SMAD6 and SMAD7 also bind to PA1, but this binding is not observed with PTIP. In addition, SMAD9 was again precipitated at low levels. Overall, these experiments indicate that the TGF-β SMADs but not the BMP SMADs interact directly with PTIP and PA1. Figure 1.TGF-β activated R-SMADs interact with PTIP and PA1. (A-B) HEK 293T cells were co-transfected with HA-tagged SMADs and GFP-tagged PA1 or PTIP expression plasmids. Affinity purification of GFP fusions was performed on whole cell extracts. Samples were analyzed by immunoblotting using HA, GFP and GAPDH antibodies. (A) Co-immunoprecipitation for GFP-PTIP. (B) Co-immunoprecipitation for GFP-PA1. For input control 1.5% of the extract was analyzed.

*Investigation of TGF-β and BMP target genes in U-2 OS* -- Previous studies have identified TGF-β and BMP signaling target genes in cell systems like the HaCaT keratinocytes and osteoblast BMP inducible C2C12 myoblast cell lines.[@cit0025] The human osteosarcoma derived cell line U-2 OS is easily transfectable and efficient siRNA-mediated knockdown of gene expression can be obtained.[@cit0029] To investigate a functional link of TGFβ with PTIP and PA1, mRNA expression of known TGF-β and BMP target genes was tested for TGF-β or BMP sensitivity in U-2 OS cells ([Fig. 2A](#f0002){ref-type="fig"} and [2B](#f0002){ref-type="fig"}). TGF-β treatment increased mRNA expression of the *SERPINE1, PMEPA1, SKIL* and *SMAD7* genes 2 to 4-fold, whereas inhibition of TGF-β signaling with the small molecule inhibitor SB-431542 reduced target mRNA expression by 50--90% ([Fig. 2A](#f0002){ref-type="fig"}). *SMAD6* expression remained unaffected. The well-known BMP target genes *ID1, ID2* and *ID3* displayed a 50--60% reduction in expression on TGF-β stimulation, while TGF-β inhibition stimulated expression of these genes to approximately 3-fold. BMP stimulation induced gene expression of *SKIL, SMAD7, SMAD6, ID1, ID2* and *ID3* between 2- and 5-fold, while *SERPINE1* and *PMEPA1* were unaffected ([Fig. 2B](#f0002){ref-type="fig"}). Based on the response to TGF-β and BMP stimulation, we categorized the genes into four groups ([Table 1](#t0001){ref-type="table"}). The first group is TGF-β responsive and consists of genes *SERPINE1* and *PMEPA1*. The second group is both TGF-β and BMP responsive and consists of *SKIL* and *SMAD7. SMAD6* belongs to the third group and is BMP responsive. And the fourth group consists of genes that become activated by BMP, but are repressed upon TGF-β stimulation. Expression of members of the MLL3 or MLL4 methyltransferase complexes is not affected by stimulation or repression of either TGF-β or BMP (Fig. S1A and S1B). Figure 2.Investigation of TGF-β and BMP target genes in U-2 OS cells. (A-B) Gene expression analysis of TGF-β and BMP target genes. (A) U-2 OS cells were treated with 10 µM SB-431542 inhibitor for 24 h and subsequently stimulated with 10 ng/ml TGF-β for 6 h as indicated. (B) U-2 OS cells were treated with 100 nM LDN-193189 inhibitor for 24 h and subsequently stimulated with 10 ng/ml BMP for 6 h as indicated. (A-B) Samples were analyzed using qRT-PCR. Bars represent average expression corrected for *ACTIN* and normalized to the siNT control. Error bars represent standard deviation. Technical replication n = 3 for all samples. Table 1.Genes and TGF-β and BMP responses.GENETGF-ΒBMPGROUP*SERPINE1*↑--TGF-β responsive*PMEPA1*↑--TGF-β responsive*SKIL*↑↑TGF-β and BMP responsive*SMAD7*↑↑TGF-β and BMP responsive*SMAD6*--↑BMP responsive*ID1*↓↑BMP responsive, TGF-β repressed*ID2*↓↑BMP responsive, TGF-β repressed*ID3*↓↑BMP responsive, TGF-β repressed

*PTIP and PA1 knockdown reduces TGF-β specific target gene expression --* To investigate the interaction between TGF-β signaling with PTIP and PA1 in the context of MLL3 and MLL4 protein complexes, siRNA-mediated knockdown efficiencies of *PTIP* and *PA1* expression were analyzed in U-2 OS ([Fig. 3](#f0003){ref-type="fig"}). Reduction in expression was tested using qRT-PCR for all genes and immunoblot analysis. mRNA expression analysis showed knockdown efficiencies of 70--95% for *PA1, PTIP* and *SMAD4* ([Fig. 3A](#f0003){ref-type="fig"}). For *MLL3* and *MLL4* a single round of knockdown yielded mRNA knockdown efficiencies of approximately 50% (data not shown). To obtain a better knockdown, cells were transfected twice to obtain a knockdown efficiency of 70--90% ([Fig. 3B](#f0003){ref-type="fig"}). Immunoblotting confirmed the expression analysis and, in addition, this showed a strong reduction of H3K4me3 levels with *ASH2L* knockdown ([Fig 3C](#f0003){ref-type="fig"}). This reduction is in line with results from our previous studies where ASH2L but not the enzymatically redundant MLL3 and MLL4 were identified as regulators of global H3K4 methylation levels in an unbiased siRNA screen.[@cit0029] Figure 3.Knockdown efficiency of siRNA treated U-2 OS. (A-C) Cells were reverse transfected with siNT, siPA1, siPTIP, siPA1 + siPTIP or siSMAD4 or with siNT, siASH2L, siMLL3 or siMLL4 and treated again after 24 h and collected after 72 hours. (A-B) Samples were analyzed using qRT-PCR. Bars represent average expression corrected for *ACTIN* and normalized to the siNT control. Error bars represent standard deviation. Technical replication n = 3 for all samples. (C) Samples were analyzed on immunoblot using PA1, SMAD4, ASH2L, H3K4me3, H3 and Tubulin antibodies. \* indicates nonspecific antibody background binding.

Next, expression levels of the previously-tested TGF-β and BMP target genes were investigated. *SERPINE1* and *PMEPA1* gene expression was reduced upon *PA1, PTIP* and the combination of *PA1* and *PTIP* knockdown, strongly suggesting a functional link ([Fig. 4A](#f0004){ref-type="fig"}). Interestingly, the BMP stimulated genes *ID1, ID2* and *ID3* ([Fig. 2B](#f0002){ref-type="fig"}) were not affected after *PA1* or *PTIP* knockdown ([Fig. 4A](#f0004){ref-type="fig"}), suggesting a specific link between TGF-β signaling and PA1 and PTIP to this subgroup of genes, but not to the BMP stimulated genes. *SMAD6* mRNA expression is induced after *PA1* knockdown. However, this does not seem to be linked to PTIP, because knockdown of PTIP does not affect expression of *SMAD6*. PA1 and PTIP are present in both the MLL3 and MLL4 complexes, but also as an independent hetero-dimeric complex. To investigate involvement of the MLL3 and/or MLL4 histone methyltransferase complexes, we determined the effects after *MLL3* or *MLL4* siRNA knockdown. Interestingly, knockdown of *MLL4* but not *MLL3* resulted in reduced expression of the *SERPINE1* and *PMEPA1* genes, suggesting that PA1 and PTIP mediate TGF-β SMAD transcription as part of the MLL4 complex ([Fig. 4B](#f0004){ref-type="fig"}). Knockdown of *MLL4* resulted in induced expression of BMP induced genes *SMAD6, ID1, ID2* and *ID3*. Figure 4.TGF-β target genes are selectively affected by PA1 and PTIP knockdown. (A-B) Gene expression analysis of TGF-β and BMP target genes and SET/MLL complex member genes. (A) U-2 OS cells were reverse transfected with siNT, siPA1, siPTIP, siPA1 + siPTIP or siSMAD4. (B) Cells were reverse transfected with siNT, siASH2L, siMLL3 or siMLL4 and treated again after 24 h to enhance knockdown efficiency. (A-B) Samples were analyzed using qRT-PCR. Bars represent average expression corrected for *ACTIN* and normalized to the siNT control. Error bars represent standard deviation. Technical replication n = 3 for all samples.

Overall, these data indicate that TGF-β mediated transcription activation involves the PA1 and PTIP subunits of the histone methyltransferase complex MLL4.

Discussion {#s0003}
==========

SMAD-mediated signaling results in the altered mRNA expression of selected gene sets. Although TGF-β and BMP signaling has been studied extensively, relatively little is known about the downstream coactivator complexes that cooperate with SMAD signaling to facilitate target gene transcription. Both TGF-β and BMP SMAD signaling complexes have been shown to recruit the co-activating proteins CREB-binding protein (CBP), p300 and the PCAF subunits of the SAGA and ATAC histone acetyltransferases to promote target gene transcription.[@cit0006] We show that TGF-β- but not BMP-activated SMADs interact with the MLL4 methyltransferase complex suggesting a TGF-β-specific target gene response pathway. The SMAD2, 3 and 4 proteins interact directly with the PA1 and PTIP proteins in transient transfection experiments. Knockdown of *PA1, PTIP* and *MLL4* result in reduced expression of the TGF-β responsive genes *SERPINE1* and *PMEPA1*.

MLL3 and MLL4 methyltransferase complexes are required for methylation of H3K4 and for demethylation of H3K27 at enhancer elements in the genome.[@cit0016] Recently, MLL4 was described to be essential for cell fate transition by recruiting p300 to the enhancer sites, independently of its methyltransferase activity.[@cit0030] Furthermore, motif analysis showed SMAD2/3 binding sites to be enriched at MLL4 occupied active enhancers.[@cit0030] Additionally, UCSC genome browser track analysis for SMAD3 and MLL4 show co-localization for the TGF-β responsive genes SERPINE1 and PMEPA1 (Fig. S2).

Both *SMADs* and *MLL* methyltransferase genes are often found mutated in various forms of cancers.[@cit0031] The *SMAD2* and *SMAD4* gene have mutations in 5.7% and 9.8%, respectively in colon and rectal carcinomas. *MLL4* is most often (but not exclusively) found mutated in bladder urothelial carcinoma and uterine corpus cell carcinomas (7.1% and 8.3%, respectively). Furthermore, *MLL4* is mutated in 2.1% of all colorectal cancers. Enhancer profiling in colon cancers has shown thousands of sites that are either gained or lost H3K4me1 levels compared to healthy tissues.[@cit0032] The link between SMAD-mediated TGF-β signaling and the MLL4 methyltransferase allows for new opportunities to study and possibly identify novel treatment options for these types of cancer and, thus, the findings reported warrant further research.

Materials and methods {#s0004}
=====================

Plasmids {#s0004-0001}
--------

Gateway compatible pENTR-SMAD vectors[@cit0024] were recombined with pMT2SM-HA in an LR reaction according to manufacturer\'s instructions (Thermo Fischer Scientific). GFP-PTIP and GFP-PA1 expression vectors were described before.[@cit0018]

Cell culture {#s0004-0002}
------------

Cells were grown in Dulbecco\'s Modified Eagle\'s Medium (DMEM) containing 1 g/L or 4.5 g/L glucose for U-2 OS or HEK 293T respectively supplemented with 10% v/v fetal bovine serum, 10 mM L-glutamine, 100 U/mL penicillin and 100 U/mL streptomycin.

Stimulation and inhibition of TGF-β or BMP signaling {#s0004-0003}
----------------------------------------------------

U-2 OS cells were counted and seeded 150,000 cells per well in a 6-well plate. Cells were left overnight to attach. Cells were treated with 10 µM SB431542 (\#616461, Calbiochem) or 100 nM LDN193189 (SML0559, Sigma- Aldrich) to inhibit TGF-β or BMP signalling, respectively. After 24 h the cells were stimulated with 10 ng/mL TGF-β1 (\#8915LC, Cell Signaling) or 10 ng/mL rhBMP-2 (355-BEC, R&D systems) for 6 h and collected for mRNA expression analysis.

siRNA transfection {#s0004-0004}
------------------

U-2 OS cells were transfected using a reverse transfection protocol with Hiperfect (Qiagen) transfection reagent according to the manufacturer\'s instructions. In short: 125 μL of a SMARTpool of four siRNAs (25 nM each) was dispensed in a 6-well plate (657165, Greiner bio-one). Transfection mix (10 μL Hiperfect in total volume of 375 μL Opti-MEM \[Invitrogen\] per well) was added, followed by 30 minutes incubation at room temperature. After this 70,000 U-2 OS cells/well were added in 2 mL. Cells treated with siRNA against genes listed in [Fig. 3B](#f0003){ref-type="fig"} were treated again 24 h after cell seeding. Cells were collected 72 h after the first transfection.

Transient transfection, whole cell extracts and immunoprecipitation {#s0004-0005}
-------------------------------------------------------------------

HEK 293T cells were counted and seeded at 150,000 cells per well in a 6-wells plate. Cells were left overnight to attach and expression vectors were transfected using polyethyleneimine (PEI). Cells were washed once with PBS and cell extracts were collected in whole cell extract buffer (50 mM Tris-HCl pH 8.0, 10% glycerol, 100 mM NaCl, 10 mM MgCl~2~, 0.5 mM DTT, 0.1% NP-40 and 1x protease inhibitor \[Complete Protease Inhibitor Cocktail, Roche\]). GFP affinity purification was essentially performed as described up to sample elution.[@cit0034]

Immunoblot analysis {#s0004-0006}
-------------------

Cells were lysed in sample buffer (160 mM Tris-HCl pH 6.8, 4% SDS, 20% glycerol, 0.05% bromophenol blue) and equal amounts of protein were separated using 10% or 15% SDS-PAGE gels and transferred onto PVDF membrane. The membrane was developed with the appropriate antibodies and ECL and scanned using ChemiDoc Touch Imaging System (Bio-Rad).

Antibodies {#s0004-0007}
----------

Antibodies were used from the following sources: ASH2L (kind gift from Winship Herr), GAPDH (clone 6C5, mAb374, Millipore), GFP (kind gift from Geert Kops), H3 (ab1791; Abcam), H3K4me3 (pAb003-050, Diagenode),[@cit0029] HA (3F10-HRP, Roche), PA1 (kind gift from Junjie Chen), SMAD4 (\#9515, Cell Signaling), α-Tubulin (DM1A, CP06, Calbiochem).

Expression analysis qRT-PCR {#s0004-0008}
---------------------------

Cells were lysed and total RNA was isolated from cells using RNeasy kit (Qiagen) including a DNase treatment using RNase-Free DNase (Qiagen) according to manufacturer\'s instructions. 500 ng of total RNA was used for cDNA synthesis (Superscript II, Invitrogen) using random primers. A 25 µL qRT-PCR reaction was performed in a CFX Connect Real-Time PCR Detection System (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) Primers used for qRT-PCR can be found in [Table 2](#t0002){ref-type="table"}. Table 2.Primers used for qRT-PCR.PrimerSequenceACTIN FwAGAAAATCTGGCACCACACCACTIN RvAGAGGCGTACAGGGATAGCAPA1 FwCCCAGAGCGAAGAGGAGAGAPA1 RvGTGGGCATGTGTGGTTTTTCCPTIP FwCATCGACCCGCAGGTTATTCAPTIP RvGAGCTTCTCCCACCTCTGGAASH2L FwTGCTGTGTCTACTAGTGGGAATTTASH2L RvTTGGCTCCTCGTCCTTTTCMLL3 FwCCACGAAAACAAAGAGGACAGMLL3 RvTGGGTGCTTACACTTACACAAGATMLL4 FwGTCTTCACTGACGCCTCTCCMLL4 RvGCAGCATGTCAGCCTCTTTTSMAD4 FwCCTGTTCACAATGAGCTTGCSMAD4 RvGCAATGGAACACCAATACTCAGKDM6A FwCTGCACAAGTAAAAGCAACTGTCKDM6A RvCTTTTGGAGATACTGAATAGCATAGCSERPINE1 FwAAGGCACCTCTGAGAACTTCASERPINE1 RvCCCAGGACTAGGCAGGTGPMEPA1 FwCTGTCTGCACGGTCCTTCATPMEPA1 RvCCACAGGCATCCTTCTGAGGSKIL FwGAGGCTGAATATGCAGGACAGSKIL RvCTTGCCTATCGGCCTCAGSMAD7 FwTCAAGAGGCTGTGTTGCTGTGSMAD7 RvTGGTTTGAGAAAATCCATCGGGTSMAD6 FwTTCTCAGACGCCAGCATGTCSMAD6 RvGCCCTGAGGTAGGTCGTAGAID1 FwCAGGGACCTTCAGTTGGAGCID1 RvAACGCATGCCGCCTCGID2 FwTGACCACCCTCAACACGGATID2 RvCATGAACACCGCTTATTCAGCCID3 FwGAGTCCCGAGAGGCACTCAID3 RvCTCGGCTGTCTGGATGGGAA
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